

Barriers and facilitators of Highly Active Antiretroviral Therapy (HAART) adherence among HIV-positive Women in Southern Ethiopia: A Qualitative study

Alemayehu Abebe Demissie^{1*}, Elsie Janse van Rensburg²

1 Hawassa University College of Medicine and Health Sciences, Hospital Public Health, Ethiopia

2 Department of Health Studies, University of South Africa (UNISA), Pretoria, South Africa

*aleab27@yahoo.com

Abstract

Background

Adherence to Highly Active Antiretroviral Therapy (HAART) medication is the major predictor of HIV/AIDS treatment success. Poor adherence to HAART creates the risk of transmitting HIV, deteriorating health conditions, treatment failure, increased occurrences of drug-resistant HIV, morbidity and mortality. The objective of this study was to explore and describe the experiences of HAART adherence among HIV-positive women in Southern Ethiopia.

Methods

Semi-structured in-depth interviews (IDIs) were conducted with 12 HIV-positive women in Southern Ethiopia who are adhering and non-adhering to HAART. Interviews were conducted in the local Amharic language and audio recorded with permission from the participants. The interviews were transcribed verbatim, coded for themes, categories and sub-categories and analyzed using a thematic data analysis technic.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Results

The findings of the study reflected two themes: barriers and facilitators of HAART medication adherence among HIV-positive women. Barriers and facilitators were further categorized into 5 categories. These included patient-related factors, treatment-related factors, psychosocial-related factors, family and community-related factors, and healthcare services-related factors. These categories were further divided into 22 sub-categories. Busy schedule, forgetting the doses, rituals of religion, economic constraints, drug side-effects, pills burden and size, misconceptions about HIV, negative attitudinal disposition towards HAART, refusal to adhere to HAART, depression, lack of hope and courage, stigma and discrimination, relationship with healthcare providers, a working day of HAART clinic, and long waiting time were identified as barriers to HAART adherence. While, family responsibilities, reminder devices, dosage formulation, perceived benefit of HAART, family support, adherence to supporting peer groups, and adherence to counselling/education were identified as facilitators of HAART adherence.

Conclusions

Adherence to HAART medication is a major challenge among HIV-positive women in Southern Ethiopia. Therefore, tailored strategies to enhance HAART medication adherence should be targeted addressing the barriers identified in the study.

Introduction

The accessibility of antiretroviral therapy (HAART) for HIV/AIDS patients has increased rapidly globally, reaching 28.7 million in 2021 from 7.8 million in 2010. However, only 68% of these individuals are virally suppressed, indicating sub-optimal HAART adherence [1]. As

less viral suppression is associated with sub-optimal HAART adherence, the global less viral suppression (only 68%) in HIV-positive individuals indicates that sub-optimal (poor) adherence to HAART is a global challenge in HIV/AIDS treatment [2]. Ethiopia, one of the most affected countries by HIV epidemics, has a high prevalence of HIV among women, with 61.1% of all HIV-positive individuals being female [3]. In 2017, there were 414,854 patients, including 21,146 children under 15, taking HAART and the national ART need was 551,630 for adults in Ethiopia[4]. Good adherence to HAART is necessary for achieving the best virological response and reducing drug resistance risk, morbidity and mortality [5, 6]. A research study conducted in Ethiopia with 339 people diagnosed with HIV revealed that 25.4% had poor adherence to their medication [7]. Similarly, another study done in Ethiopia showed that only 73.1% of patients were adherent to their HAART [8]. Various factors contribute to poor adherence, including patients and their families, socioeconomic factors, medication, and health providers and systems. Studies have shown that women face numerous challenges in ensuring adherence to HAART, such as education, age, income, stigmatization, and socio-familial support [9]. Women are also responsible for household activities, which can further disadvantage them in balancing family and social life [10]. There is a lack of studies conducted on HIV-positive women's adherence to HAART in Ethiopia specifically. To address this issue, programs and care providers need to tailor a combination of feasible interventions to maximize adherence of women to HAART based on individual barriers and opportunities globally and in Ethiopia. Therefore, to address the gap in treatment adherence, this study aims to develop a better insight into adherence among HIV-positive women on ARV treatment in Southern Ethiopia.

Methodology

Design and setting

The study used an exploratory qualitative research design to gain new insights and understandings based on the themes, categories and sub-categories that emerge from the data.

The study applied the consolidated criteria for reporting qualitative research (COREQ), which is a set of criteria for reporting qualitative research [11].

Study setting and sampling procedures

The researchers used a purposive and convenient sampling procedure to select the Southern Ethiopia region and the three urban hospitals that were studied. This sampling technique was chosen to select the southern region from the nine regions of Ethiopia and the study hospitals from 21 urban public hospitals found in Southern Ethiopia based on convenience (most accessible to and easily reached by the researchers) and HIV-positive individuals' load. The purpose of the selection of these three urban public hospitals was due to their high volume (load) of HIV-positive individuals who were taking HAART as compared to other health facilities in Southern Ethiopia

Women in Southern Ethiopia who are HIV positive and adhering or non-adhering to HAART were purposively and conveniently sampled based on the eligibility criteria. Twelve participants (six adhering and six non-adhering women diagnosed with HIV) were purposively and conveniently sampled for the in-depth interviews. Two more interviews were performed to ensure data saturation was reached.

Interview tool development and data collection procedure

A semi-structured interview guide was developed based on the literature reviewed. An in-depth interview was chosen as a data collection method for this study because the research topic is sensitive, and it would enhance the confidentiality and anonymity of participants. The intended data were

collected from women in Southern Ethiopia who are HIV-positive and adhering or non-adhering to HAART. The in-depth interviews were regulated by the interview guide, and probing questions were asked where more detail was needed. Field notes allowed the researchers to remember the behaviours, impressions, nonverbal actions, and environmental contexts that would not be adequately captured via the audio-tape during the in-depth interviews.

Data collection and analysis

We conducted the in-depth interviews with 12 HIV-positive women. The IDIs were audio-recorded (with the participant's permission). The interviews were conducted in Amharic, a local language most people in Ethiopia speak. The in-depth- interviews last approximately 60-70 minutes. The researchers used field notes in the in-depth interviews to substantiate the findings from this qualitative data-gathering technique [12]. Data were collected from June 3 to 25, 2023 until data saturation was reached. The researchers translated the audio-recorded data from Amharic into English for analysis. Data from in-depth interviews and field notes were analyzed using the thematic analysis method, which is a search across a data set (interviews, field notes, or a range of data) to find repeated patterns of meaning. The researchers used the Nvivo 12 qualitative data analysis computer program for data analysis [13]. The researchers used thematic analysis for the current study since it is recommended as a convenient method for employing within a participatory research paradigm with participants as collaborators [14]. Finally, some verbatim quotes from HIV-positive women are used to illustrate the sub-categories.

Ethical Considerations, Rigour, and Trustworthiness

This study obtained scientific approval from the scientific committee (Department of Health Studies and ethical clearance (Ref: HSHDC/463/2015) from the College Research Ethics Committee of the University of South Africa (UNISA). Similarly, permission to carry out the

study was asked for and gained from the stakeholders, including the Southern Regional Health Bureau and the three public hospitals where the study was conducted. Confidentiality was ensured at all stages of the process. Informed consent was obtained from the participants prior to the interviews. Participants gave written informed consent before enrollment using the approved consent forms. Participants were assured that refusal to participate or withdrawal from the study would not affect their access to healthcare services at the clinic. The researchers considered the essential values of ethical research, which incorporate respect for human autonomy and dignity, justice, beneficence, and non-maleficence [15]. To ensure the reliability and validity of the results, different techniques were applied. These included developing a rapport with participants, creating a coding system, implementing peer review for themes and sub-themes, triangulation of data sources (including interview transcripts and field notes), and providing a thorough contextualised data description [16]. The specific names of the study public hospitals were not disclosed in the study to maintain anonymity. Therefore, the study hospitals remain unidentified to readers or any other individuals. The 12 interviews participants (e.g., P12, P7, etc.), were also not identified by name, and the specific study site is known only to the researchers. Though, the ages of the 12 participants were mentioned in the participants' quotes, given the large number of patients across the 21 public hospitals (from which the 3 study hospitals were selected), it is not possible for anyone to ascertain the age of each participant. The participants' codes/IDs (e.g., P12, P7, etc.), we want to emphasize that these codes were assigned by the researchers solely for the purpose of this research. They are not related to any clinic or healthcare provider IDs used for medical follow-up. As a result, no individual, including the patients themselves, can identify any participant based on these codes.

Results

Socio-demographic characteristics of study participants

A total of 14 HIV-positive women with varying ages and educational levels participated in the in-depth interview. Their age range was from 20 to 59 years. Of the participants, 6 women were adhering and 6 women were non-adhering to their HAART medication.

Table 1 provides the demographic and background characteristics of the participants involved in the in-depth interview. The participants' demographic and background characteristics suggest a diverse group with varying backgrounds and life experiences.

Table 1 Summary of demographic characteristics of HIV-positive women who participated in in-depth interviews

Characteristics (N=14)	Number	Total (%)
Age (yrs.)		
20–29	3	25%
30–39	5	41.7 %
40–49	3	25%
50–59	1	8.3%
Adherence status		
Adherent to HAART	6	50%
Non-adherent to HAART	6	50%
Educational level		
No education	2	16.7%
Primary (1–8)	5	41.7%
High school (9-12)	4	33.3%
Tertiary (University)	1	8.3%
Marital Status		
Married	4	33.3%
Divorced	2	16.7%

Widowed	3	25%
Single	3	25%
Employment status		
No work	2	16.7%
Housewife	4	33.3%
Labourer	1	8.3%
Government	0	0%
Private organisation	5	41.7%

Themes, categories, and sub-categories

The experiences of HAART adherence among HIV-positive women were described in two themes. These themes include Barriers to HAART medication adherence and Facilitators of HAART medication adherence. Barriers to HAART medication adherence among HIV-positive women were grouped into five categories and fifteen sub-categories (Table 2). While facilitators of HAART medication adherence were grouped into five categories and seven sub-categories (Table 3).

Table 2 Barriers to HAART medication adherence among HIV-positive women in Southern Ethiopia

Themes	Categories	Sub-categories	Selected HIV-positive women quotes
		Busy schedule	<ul style="list-style-type: none"> • “Since I am busy with my hectic daily schedule, I sometimes miss my ARV medications. When I remember that I have not taken my pills, I would take them as soon as possible on the same day or the next day. Taking my pills like this has been my routine experience ever since I started the medications; it is very comfortable for me. Healthcare providers told me that I was supposed to take the prescribed ARVs at the right time regularly; but ... it is impossible to do that.” (P6, non-adherent). • “I am busy at my work and when I am busy, I usually forget to take them [HAART medication]. Sometimes if you are focused on and busy at your work, you will not know even what you are doing.” (P8, non-adherent).
		Forgetting the doses	<ul style="list-style-type: none"> • “ ... I sometimes do not recognise the alarm tone and thus, I miss the pills and forget them until the night dose taking time.” (P5, adherent). • “The other problem I encounter is that I am unemployed so sometimes something happens; I have depression and forget to take my pills.” (P14, non-adherent).

		Rituals of religion	<ul style="list-style-type: none"> • “God is my only hope. No one will think about his/her health without him. If you look at the ART drug, it will never and ever work without GOD’s permission. I sometimes take my medications along with holy water that I get from a church known for its curative power over any sin. During the time; when I went to a monastery, I would never take my ARV medications for about two to three weeks because of the religious doctrine.” (P8, non-adherent). • “I have a friend who is HIV positive; she told me that she got cured of HIV after she had been baptized with holy water. She has considered herself as if she is free from HIV and thus, she has stopped her medications since before last year.” (P6, non-adherent).
--	--	---------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	Patient-related factors	Economic constraints	<ul style="list-style-type: none"> • “In simple language, taking the pills alone is not working rather they may cause nausea, vomiting, nightmares and weight loss. In addition to taking the medications on time, one should get nutritious food. However, some needy individuals like me have no money to buy and eat such food. Therefore, I sometimes become forced to skip the pills as I can’t get something to eat before I take the daily pills.” (P2, non-adherent). • “Sometimes I go to the HAART clinic one or two days after the appointment day if I do not have money at hand for transportation.” (P14, non-adherent).
	Treatment-related factors	Drug side-effects	<ul style="list-style-type: none"> • “If you simply try to take HAART the whole time as per the healthcare order, it is difficult because of its side effects, expected to take many pills daily throughout your whole life.” (P4, non-adherent).

Barriers to HAART adherence			<ul style="list-style-type: none"> • “I know some patients who fear the side effects of HAART very much and due to that they take their medications occasionally.” (P14, non-adherent).
		Pills burden and size	<ul style="list-style-type: none"> • “The size of the drug is also too big to swallow. A year before, I remember that I skipped my two doses every other week for three rounds ... if sometimes you feel exhausted due to the taking of many pills it is possible to take every other week for some time until your body has a sense of refresh.” (P5, adherent). • "I would suggest the ART pills be in the form of small size, even the form of injection if possible. I always struggle to swallow my big-size pills with water but they are stuck in my throat, pills are not comfortable to swallow, and sometimes I prefer not to take them, because of the fear of vomiting ... since my stomach is full.” (P2, non-adherent).
		Misconceptions about HIV.	

			<ul style="list-style-type: none"> • “Yes ... what I understood, unless you completely stop the medications, HIV may not be worsened to AIDS. I do not know ... This may happen due to chance.” (P8, non-adherent). • “Just like me, my husband is also HIV positive. He had started his ARV medications before I started mine. He does not have an interest in taking his [ARV] medication regularly. Though he does not take his medication regularly, he is still healthy. Currently, he is in good health condition. I think, taking this medication with some days' interruption in between doses may not have any problem for some individuals like him.” (P13, non-adherent).
		<p>Negative attitudinal disposition towards HAART</p>	<ul style="list-style-type: none"> • “We know that ARVs can't cure HIV. So, if they have no power ... why am I taking these [ARV] medications for life? For me, it is a waste of my time to take these nonsense medications ... Sometimes, I wish I didn't see these medications in my bag forever.” (P3, non-adherent).

			<ul style="list-style-type: none"> • “I don’t want to lie here, I am not afraid as there is no health care provider here with you. I always, which means during my scheduled date for medication collection, go there [HAART clinic] and collect my medications. However, I don’t take these medications daily because they are not as effective [don’t cure HIV] as other kinds of drugs unless you are lucky enough; their benefit is with luck; they are highly dangerous [body damaging] for me if I am not lucky.” (P14, non-adherent).
		<p>Refusal to adhere to HAART</p>	<ul style="list-style-type: none"> • “ ... since last year I have been missing pills many times because I have already decided that it is important for me to some extent ..., I haven’t been taking my medications timely on a regular basis and I sometimes skip my medication, there is nothing [that] happened to my health and thus I have no courage to take the pills always. I am lucky.” (P4, non-adherent).

			<ul style="list-style-type: none"> • “I have been working in a bakery for 5 years. I do not know when and how I was infected with HIV. I visited the nearby hospital for my illness and I was diagnosed with HIV then, it has now been four years. I am taking my HIV treatment pills, but there are also times I should miss these pills just to have my body rest [free from ARVs]. Anyways, missing pills is a happening condition and that is okay. If I missed the pills, I don’t like to bother about it rather I would take them the next day or then after.” (P14, non-adherent).
	<p>Psychosocial-related factors</p>	<p>Depression</p>	<ul style="list-style-type: none"> • “Oh my God... There are so many issues I have [been] thinking about ... my health condition, I also bother about my children and family ... then I go into a deep feeling of depression. During that time, I didn’t have an interest in taking medications and missed them because of the mood I had.” (P2, non-adherent).

			<ul style="list-style-type: none"> • “When I took my night pills, especially during the first six months after I started taking them, I always went into trouble sleeping during the night and became passive and depressed in the immediate morning. I stopped the pills. Finally, the doctor changed the pills and now I am relatively okay.” (P9, non-adherent).
		Lack of hope and courage	<ul style="list-style-type: none"> • “Yes, since we [HIV positive women] are females and mothers who are responsible for childcare and home management, without our partners [sexual] support in our medications [ARVs] taking, I don’t think ... the environment to be conducive to take and continue our medications for lifelong. If you lack hope in your future life, everything surrounding you seems to be dark.” (P2, non-adherent).
	Family and community-related factors	Stigma and discrimination	

			<ul style="list-style-type: none"> • “I skip my ARV medications intentionally [due to fear of stigma] many times ... because people are around me. They do not know that I am HIV positive. I always worry about what my friends/colleagues in my workplace think about me if they get a chance to know about my diagnosis of HIV while I am taking my medications in front of them.” (P4, non-adherent). • “I usually take my pills properly, especially during weekends as I have no work these times. Otherwise, what I understand from my daily routine is, that it would be impossible to take my pills in front of my colleagues in my workplace, I don’t need them to know that I have HIV ... it is very hard. If they notice that, you know what will happen. They will stigmatise me, and even they may not want to drink tea and coffee with me. The best solution for this is, to hide myself and keep silent, thus I can drink, eat and work with them.” (P3, non-adherent).
		Relationship with healthcare providers	

	Healthcare services-related		<ul style="list-style-type: none"> • “I heard from another HIV-positive woman who missed her dose that the healthcare providers shouted at her because of her interruption of HAART for some reason. Therefore, the safe way is not to tell them about my missed dose or interruption of ARV drugs.” (P2, non-adherent). • “Sometimes I observe the healthcare providers blame their patients as they do not take their pills according to the healthcare provider’s instructions. That is the reason why I kept such issues secret otherwise my future relationships with health care providers will be affected.” (P6, non-adherent).
		Working day of HAART clinic	<ul style="list-style-type: none"> • “For me, I would have been comfortable, if the HAART clinic opened at weekends to supply medications for us because I was always very busy with my work during the whole day except at weekends.” (P13, non-adherent).
		Long waiting time	

			<ul style="list-style-type: none">• “When I have a laboratory examination ordered by the doctor, I always stay for a long time. I told the doctor last time not to send me [to the] Laboratory department for any kind of laboratory investigation. If you have a laboratory investigation you may stay there the whole day and thus, you may even leave the clinic without taking your medication.” (P4, non-adherent).
--	--	--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Theme 1: Barriers to HAART Medication Adherence

Category 1: Patient-related

Busy schedule

Participants (HIV-positive women taking HAART) reported some patient-related factors as barriers to their HAART medication adherence. These women highlighted their difficulties in keeping up with their HAART medication regimen due to their hectic schedules and employment obligations. Their hectic lifestyles frequently cause occasional missed dosages and difficulty adhering to the suggested right timing. During the IDIs, women discussed some barriers which impeded them from taking their HAART medication properly.

Forgetting the doses

Forgetting the HAART doses was among the issues reported by most participants in IDIs as a challenge for optimal HAART adherence. HIV-positive women may have a busy lifestyle that includes travelling somewhere away from their homes, engaging in different social affairs (weddings, funerals, social gatherings, and others), and personal reasons. Thus, these situations may create mental stress and insufficient time to remember their doses regularly, resulting in missed HAART doses.

One of the participants indicated that they occasionally forget to take their medication as directed because they get caught up in their everyday tasks or work.

Rituals of religion

Some participants of the IDIs highlighted how religious rituals, particularly fasting during Ramadan, or following Orthodox Church teachings, hindered their adherence to HAART

medication. They believed that relying on their faith and religious practices would bring blessings and even potential cures for their health conditions. As a result, they chose to skip or delay taking their HAART medication during these religious periods. Despite their poor HAART adherence, some participants perceived themselves as healthy and attributed their well-being to the combination of religious rituals and medication.

Economic constraints

The study participants mentioned several financial barriers that prevented them from taking their HAART medication as prescribed by healthcare providers. Mentioning some symptoms like nausea, vomiting, nightmares, and weight loss as examples, they stressed the negative consequences of taking the medications without adequate nutrition. They frequently had to skip doses because their financial constraints made purchasing nutritious food impossible.

Category 2: Treatment-related factors

Drug side-effects

Participants in the study expressed concerns about the side effects and organ damage that may result from using HAART medications. These worries and experiences exacerbate their difficulties in adhering to the HAART medication and the overall treatment plan. They indicated that missed doses would not worry them because their bodies would have a respite from the HAART medication.

Pills burden and pill size

Various reasons affect HIV-positive individuals' adherence to their prescribed HAART medication regimen. The burden and size of pills are some of the factors that affect adherence to the lifelong treatment regimen for HIV/AIDS.

According to the participants' views, taking HAART medication presented problems with their adherence due to the number and size of pills they had to take and their concerns about fatigue, discomfort, and swallowing big pills.

Some HIV-positive women who participated in the IDIs showed a misconception about the need for strict adherence to HAART medication. They think that periodic lapses in taking their HAART medication will not have a significant negative impact on their health or make their HIV situation worse. They attribute this belief to personal experiences or anecdotes of others who have seemingly maintained good health despite not strictly following the healthcare providers' prescription for the HAART medication regimen.

Category 3: Psychosocial-related factors

Negative attitudinal disposition towards HAART

In this qualitative study, some participants who took part in the IDIs expressed negative attitudes towards HAART medication, which hindered their HAART medication adherence. They expressed the negative attitude that HAART medication could not cure HIV and saw taking them as a waste of time, with potential long-term ineffectiveness and harm to their bodies.

Refusal to adhere to HAART

Refusal to adhere to HAART refers to the HIV-positive individual's active decision not to adhere to the HAART medication as prescribed by healthcare providers. One major obstacle was the refusal to adhere, with some individuals choosing to miss their HIV treatment pills periodically to give their bodies a break from ARVs. Some held a mistaken belief that taking ARV medications daily without breaks could be harmful. They perceived no difference between daily and alternate-day intake of the pills and, as a result, decided to take their medications every other day. A barrier was a false sense of security, where certain participants believed they were lucky

enough to evade negative consequences despite frequently skipping their medication. This belief resulted in a decreased drive to maintain consistent pill intake.

Depression

In the IDIs, depression has been identified as an obstacle preventing HIV-positive women from taking their HAART medication. Highly Active Antiretroviral Therapy (HAART) has been related to depression in some HIV-positive women, which has caused them to skip doses in order to prevent potential health issues:

Lack of hope and courage

Lack of hope and courage were found to be obstacles preventing study participants from taking their HAART medication. Some IDI participants expressed feelings of hopelessness, citing various reasons such as unsupportive partners, social pressure, the incurability of the disease, and fear of discrimination at work. Due to these factors and the gloomy outlook on their future, some HIV-positive women who participated in IDIs had become unmotivated to take their prescribed HAART medication consistently and even thought about stopping their treatment entirely.

Category 4: Family and community-related factors

Stigma and discrimination

Many HIV-positive women indicated worries about taking their medications in front of coworkers at the workplace. They were concerned about possible negative consequences, including stigma, social exclusion, or rejection if others discovered their HIV status. Some HIV-positive women miss their medications on purpose due to this worry and apprehension.

Category 5: Healthcare services-related

Relationship with healthcare providers

HIV-positive women looking for help and counselling for their health were facing challenges as a result of unpleasant encounters with healthcare providers. The challenges with HAART medication adherence have been exacerbated by such treatment at the HAART clinic because they feel discouraged and unsupported. The study participants reported several negative experiences with the healthcare providers.

Working days of HAART clinic (No service at weekends)

Due to the clinic's operation hours conflicting with their working hours, many HIV-positive women, especially those who work during the week, find it challenging to pick up their ARV medications. Long absences from collecting medications as a result of this led to non-adherence.

Long waiting time

Participants often encounter long waiting times, especially during laboratory examinations or when there is a high influx of patients at the clinic. These extended waiting periods cause discomfort and inconvenience, making it difficult for them to access their medications and adhere to their HAART treatment prope

Table 3 Facilitators to HAART medication adherence among HIV-positive women in Southern Ethiopia

Themes	Categories	Sub-categories	Selected HIV-positive women quotes
	Patient-related factors	Family responsibilities	<ul style="list-style-type: none"> • “But when I come to my condition, I have been taking my HAART due to the benefits I get from it. The major reason as I mentioned above is my child because I should live healthy to take care of her.” (P12, adherent). • “When my phone’s alarm is ringing, I immediately go to the shelf where my pills are found and then I take them with a glass of water.” (P7, adherent).
		Reminder devices	<ul style="list-style-type: none"> • “I never missed any dose after I used the mobile phone reminder. I always put my mobile on periodic vibration; when it starts to vibrate it reminds me that is the right time to take my pills.” (P7, adherent).

Facilitators of HAART adherence			<ul style="list-style-type: none"> • “... Due to that, I always become tired and sleep without taking my medications and eating my dinner. However, the clock’s alarm in my home reminds me ... then I wake up and take my medications immediately after my dinner. Really that helps me.” (P13, non-adherent).
	Treatment-related factors	Dosage formulation	<ul style="list-style-type: none"> • “Taking one pill per day is helpful as it prevents the side effects and burden which might occur from many pills. Healthcare providers should prescribe like this [one pill per day] for their patients.” (P8, non-adherent). • “Thanks to technology, these days ARVs are easy to take as they are prepared in a single pill and small size form. This motivated us [HIV-positive women] to take them timely.” (P12, adherent).
	Psychosocial-related factors	Perceived benefit of HAART	<ul style="list-style-type: none"> • “... now my health condition has improved well. I know this is because of HAART, thus I will strictly follow the advice given by the health professionals on how I should take the ARVs regularly.” (P7, adherent).

			<ul style="list-style-type: none"> • “It [HAART] is a miracle; it is because of that I look like this. I was not able to even get out of my bed, I was very weak to perform simple home activities before I was diagnosed with HIV and started to take my medications. Now I am very healthy and doing my workplace and work activities. I am now very strong as I am taking my medication by collecting it every three months from this hospital, thanks to God again and again.” (P10, adherent).
	Family and community-related factors	Family support	<ul style="list-style-type: none"> • “Therefore, family and social support are very helpful in taking HAART as it helps the patient have better adherence to HAART.” (P2, non-adherent). • “As I mentioned, my husband and me support each other on our treatment as well as on other family issues, I think, that is the main reason for us to take our medications properly without missing or interrupting.” (P7, adherent).
		Adherence supporting peer group	

			<ul style="list-style-type: none"> • “As I’m an adherence supporter, I usually educate some HIV-positive patients by giving this information about what HAART means.” (P10, adherent). • “I got a lot from the adherence support women’s experiences. I remember that dark week. I even decided to commit suicide when I first heard my blood test result, which revealed that I had HIV. I did not tell this to anyone else except health professionals and these HIV-positive women group [a small group of HIV-positive women working on counselling and life experience sharing]. They changed my mind to positive thinking [positive outlook about living with HIV and ARV medications]. Now I am taking my medications regularly without a problem.” (P5, adherent).
	Healthcare services-related	Adherence to counselling and education	<ul style="list-style-type: none"> • “Every time when I visit the HAART clinic, healthcare providers provide us with counselling and education on HIV medication and treatment, which is very helpful for our treatment and adherence.” (P1, adherent).

			<ul style="list-style-type: none">• “The adherence counselling being provided by the healthcare providers also helped me to understand the medication; thus, I am taking the medication properly.” (P10, adherent).
--	--	--	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Theme 2: Facilitators of HAART Medication Adherence

Category 1: Patient-related

Family responsibilities

For many participants, the desire to be responsible for their children and ensure their well-being and education is a driver for maintaining a healthy life through proper medication adherence.

Reminder devices

In the IDIs, many participants reported that they use reminder devices. Particularly, a mobile phone alarm is a valuable reminder tool that could help HIV-positive women remember to take their HAART medication. HIV-positive women who participated in the IDIs underlined how useful these medication-reminder devices are for ensuring their regular and timely HAART medication intake.

Category 2: Treatment-related factors

Dosage formulation

The dosage formulation of the HAART medication is crucial in enhancing patients' compliance with their treatment regimen. The positive impacts of a simpler dosage formulation on participants' adherence are evident from their feedback. Participants who had to take multiple drugs twice a day in the past often felt worn out and had problems adhering to the prescribed regimen. However, with the current single-pill dosage type, they take their medication very differently, which has increased adherence.

Category 3: Psychosocial-related factors

Perceived benefit of HAART

Most participants were inspired to strictly follow their prescribed treatment plan by the benefits they observed from taking HAART medicine, particularly the notable health and general well-being improvement.

Category 4: Family and community-related factors

Family support

Participants frequently stated that having family support has a good effect on their medication-taking habits and overall treatment experience. Participants with family support are encouraged to take their HAART medication as directed by their healthcare providers and are reminded to do so. Family members can actively ensure medication adherence, give prompt reminders, and foster a positive environment.

Adherence-supporting peer group

Participants highlighted the valuable support and guidance they receive from adherence-supporting peer groups, which positively influences their medication-taking behaviour. The adherence support women's group significantly changed the participant's perspective on coping with HIV and taking HAART medicine.

Category 5: Healthcare services-related

Adherence counselling and education

Adherence counselling and education provided by the HAART clinic have encouraged participants to follow their HAART medication regimen. Continuous counselling and education have increased their awareness and consciousness regarding the importance of taking HAART medication properly. They emphasized that adherence counselling provided by healthcare providers could help them understand the importance of HAART medication and

the consequences of poor medication adherence. It also helps them address any concern they have that needs medical attention.

Discussion

In this study, HIV-positive women describe their experiences regarding their barriers and facilitators of HAART medication. These barriers include a busy schedule, forgetting the doses, rituals of religion, economic constraints, drug side-effects, pill burden and size, misconceptions about HIV, negative attitudinal disposition towards HAART, refusal to adhere to HAART, depression, lack of hope and courage, stigma and discrimination, relationship with healthcare providers, working day of HAART clinic, and long waiting times. Being busy with different activities linked to the roles of women was found to be one of the many challenges which affect the proper taking of medication among HIV-positive women. These findings of the IDIs are supported by the findings of two studies conducted in Nigeria. Being too busy was one of the reasons given by ARV users with poor adherence. Another study also identified being too busy as a significant factor influencing treatment adherence [17].

Forgetting to take HAART medication was also identified in the IDIs by participants as one of the reasons for poor medication adherence. Such problems associated with forgetting to take HAART medication in this study are consistent with findings from other studies [18, 19]. A study conducted in Northern Ethiopia found that forgetting and being away from home were prominent reasons identified for poor adherence among HIV-positive individuals receiving HAART [7]. Another barrier described by participants was spiritual activities. The spiritual activities including fasting and the use of holy water, are also mentioned in another study from Northwest Ethiopia as challenges to HAART adherence among HIV-positive individuals [20]. A study conducted in London found that some HIV-positive individuals on HAART believed their faith in God might cure HIV/AIDS [21]. Economic constraints were among the barriers

to HAART medication raised by the participants in this study. This finding is consistent with another study conducted in Uganda that the Lack of money for transport was reported as a challenge to HAART adherence [22]. Furthermore, financial challenges were one of the major barriers to HAART medication adherence among HIV-positive individuals [23].

Drug side effects appeared to be one of the major barriers to HAART medication raised by the participants in this study. This is also mentioned in the literature [24]. Those women who had developed side effects while on treatment had poor adherence to their HAART medication [25]. Moreover, other studies conducted in Ghana have revealed that medication side effects harm HAART adherence [26, 27]. The current study also explored pill burden and pill size as among the common challenges of HIV-positive women in taking their HAART medication. This challenge affects the day-to-day activities, especially the daily taking of ARV pills, and thus affects their adherence to HAART. If individuals diagnosed with HIV have some inconvenience with their HAART medication regimen, the likelihood of taking their medication at the right time and frequency will be reduced, which results in poor [21] adherence to HAART medication [28]. A similar study conducted in Dessie also indicates that HIV-positive individuals who took medications other than HAART medication were less likely to adhere to their HAART medication compared to those who did not take any non-HAART medications [29]. Some HIV-positive women who participated in this study showed a misconception about the need for strict adherence to HAART medication. Negative attitudinal dispositions towards HAART were also reported by participants as a barrier to their HAART. The study showed that participants think that periodic lapses in taking their HAART medication will not have a significant negative impact on their health or make their HIV situation worse. It is revealed that misconceptions can lead to HIV-positive individuals delaying or avoiding treatment of HIV with HAART medication, which can have negative consequences for their health and well-being. Negative perceptions or beliefs of HIV-positive

individuals of the personal need for HAART medication in HIV-positive individuals cause poorer adherence to their HAART medication regimen [30]. HIV-positive individuals' negative perception toward HAART was identified in this study as one of the multiple factors which hinder HAART medication adherence. This factor has also been reported in other similar studies [31]. Moreover, the refusal to adhere was explored as a barrier to HAART adherence in this study. Some individuals choose to miss their HIV treatment pills periodically to give their bodies a break from ARVs and this results in poor adherence. This study's findings support the findings from other studies [32, 33]. On the other hand, depression, lack of hope and courage and stigma and discrimination were raised as common barriers to HAART medication by the participants. Depression is a psychiatric disorder that manifests clinically as low mood, loss of enjoyment, decreased motivation and energy, guilt or low self-esteem, disturbed sleep or appetite, suicidal thoughts, and trouble concentrating [34]. A combination of factors, including the nature of the disease, medication side effects, social stigma and discrimination impacts their adherence to HAART negatively [35, 36]. Similarly, a study conducted in Eastern Ethiopia also reported depression as one of the factors that affect ART adherence [37]. When partner support is lacking, several challenges may arise that could affect treatment adherence, like the lack of emotional support and encouragement [38]. HIV stigma is a common problem and frequently reported barrier to HAART medication adherence among HIV-positive individuals. A study done in Kenya revealed that HIV-related stigma was found to be the major challenge for HIV-positive individuals, preventing them from taking their HAART medication properly as prescribed by healthcare providers [39]. The influence of stigma and discrimination on HAART adherence is also shared by other studies [40]. In this study, participants reported poor relationships with the healthcare providers and due to this their medication-taking practices have been affected. These findings are in support of studies also documenting that poor relationships between healthcare providers and patients can negatively impact drug

adherence [41]. The absence of services over weekends and long waiting times at HAART clinics were mentioned as barriers to HAART medication among participants. A qualitative study indicated that some patients do not have flexible work schedules that allow them to pick their medication up during clinic weekday [42]. Long waiting times at HAART clinics are a significant factor promoting poor adherence to HAART medication, according to studies in Ghana and in South Africa [43, 44].

Participants described facilitators of HAART adherence as family responsibilities, reminder devices, dosage formulation, perceived benefit of HAART, family support, adherence supporting peer groups, and adherence to counselling/education. A qualitative study conducted in Zimbabwe indicated that HAART helped HIV-positive women carry out their responsibilities as mothers in caring for their children and family members [45]. In this study, participants underlined how useful these medication reminders were to ensure their regular and timely HAART medication intake. The importance of reminder devices in medication-taking practices was revealed in different studies [46, 47]. Likewise, the current study findings indicated that a mobile phone alarm is a valuable reminder tool that could help HIV-positive women remember to take their HAART medication.

In this study, participants who had to take multiple drugs twice a day in the past often felt worn out and had problems adhering to the prescribed regimen. However, with the current single-pill dosage type, they take their medication very differently, which has increased adherence. Single-tablet regimens encourage treatment adherence since they are easier to use and have reduced toxicities [48]. On the other hand, many participants reported improvements in both their physical and overall health conditions as a result of HAART. The findings of this study on the benefit of HAART are similar to other studies [49]. Researchers found a positive association between family support and adherence to HAART medication [50]. A qualitative study in South Africa showed that patient education and counselling in the HAART clinic

facilitate treatment adherence [51]. In this study, it is reported that adherence counselling and education provided by the HAART clinic have encouraged participants to follow their HAART medication regimen.

Limitations

The study was restricted to and conducted in only three urban hospitals in one region of Ethiopia. Therefore, the findings cannot be generalised to other regions or the whole country. Another limitation of the study was the difficulty in avoiding the possibility of social desirability bias. This was during the face-to-face in-depth interviews, particularly from HIV-positive women who came to HAART clinics to collect their HAART medication, which might increase the chance of interviewees answering questions with more desirable responses instead of actual answers. Despite these limitations, we used face-to-face in-depth interviews with participants provided a rich and personal understanding of their experiences, allowing for a deeper exploration of the factors influencing adherence to HAART medication.

Conclusions

Adherence to HAART medication is a major challenge among HIV-positive women in Southern Ethiopia. In exploring the HIV-positive women's own experiences and needs an understanding of the barriers and facilitators of adherence to HAART medication can be reached. Busy schedule, forgetting the doses, rituals of religion, economic constraints, drug side-effects, pills burden and size, misconceptions about HIV, negative attitudinal disposition towards HAART, refusal to adhere to HAART, depression, lack of hope and courage, stigma and discrimination, relationship with healthcare providers, a working day of HAART clinic, and long waiting time were identified as barriers to HAART adherence. While, family responsibilities, reminder devices, dosage formulation, perceived benefit of HAART, family

support, adherence supporting peer groups, and adherence to counselling/education were identified as facilitators of HAART adherence. Therefore, understanding factors which affect adherence can help to develop tailored interventions to increase adherence and improve the health outcomes of HIV-positive women.

Data availability statement

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

Acknowledgements

We would like to express our gratitude to all the three sampled public hospitals' healthcare providers, all the participants and their families, and all of our colleagues who contributed to this study.

Author Contributions

Conceptualization: Alemayehu Abebe Demissie.

Data curation: Alemayehu Abebe Demissie.

Formal analysis: Alemayehu Abebe Demissie and Elsie Janse van Rensburg.

Investigation: Alemayehu Abebe Demissie.

Methodology: Alemayehu Abebe Demissie and Elsie Janse van Rensburg.

Supervision: Elsie Janse van Rensburg.

Writing – original draft: Alemayehu Abebe Demissie.

Writing – review & editing: Elsie Janse van Rensburg.

References

1. UNAIDS. Documents [Internet]. UNAIDS. Available from: <https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-pdf>. 2022.
2. Zewude S, Ajebe T. Magnitude of optimal adherence and predictors for a low level of adherence among HIV/AIDS-infected adults in South Gondar zone, Northwest Ethiopia: a multi facility cross-sectional study. . *BMJ Open* 2022;12(1).
3. Girum T, Wasie A, Lentiro K, Muktar E, Shumbej T, Difer M, et al. Gender disparity in epidemiological trend of HIV/AIDS infection and treatment in Ethiopia. *Archives of Public Health*. 2018;76:1-10.
4. WHO. National consolidated guidelines for comprehensive HIV prevention, care and treatment | WHO | Regional Office for Africa [Internet]. WHO | Regional Office for Africa. Available from: <https://www.afro.who.int/publications/national-consolidated-guidelines-comprehensive-hiv-prevention-care-and-treatment>. 2024.
5. Angelo AT, Alemayehu DS. Adherence and Its Associated Factors Among Adult HIV-Infected Patients on Antiretroviral Therapy in South Western Ethiopia, 2020. *Patient Preference Adherence*. 2021;15:299-308. Epub 2021/02/20. doi: 10.2147/ppa.s298594. PubMed PMID: 33603348; PubMed Central PMCID: PMC7886248.
6. Nigusso FT, Mavhandu-Mudzusi AH. Magnitude of non-adherence to antiretroviral therapy and associated factors among adult people living with HIV/AIDS in Benishangul-Gumuz Regional State, Ethiopia. *PeerJ*. 2020;8:e8558.
7. Gebreagziabher TT, Woldemariam GT. Antiretroviral treatment adherence and determinant factors among adult people infected with human immunodeficiency virus in eastern tigray general hospitals, Northern Ethiopia, 2019. *HIV/AIDS-Research and Palliative Care*. 2020:497-505.

8. Abadiga M, Hasen T, Mosisa G, Abdisa E. Adherence to antiretroviral therapy and associated factors among Human immunodeficiency virus positive patients accessing treatment at Nekemte referral hospital, west Ethiopia, 2019. *PloS one*. 2020;15(5):e0232703.
9. Peña SS, Bravo MdMP, Tomás MÁC, Martínez PA, Guillén CP, Jiménez-Ruiz I. Factors affecting adherence to antiretroviral treatment in women with HIV: A sequential mixed model research design. *Enfermeria Global*. 2021;20(2):18-34.
10. Mussida C, Patimo R. Women's family care responsibilities, employment and health: a tale of two countries. *Journal of family and economic issues*. 2021;42(3):489-507.
11. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *International journal for quality in health care*. 2007;19(6):349-57.
12. Nassaji H. *Good qualitative research*. Sage Publications Sage UK: London, England; 2020. p. 427-31.
13. Loraine B, Wick W, Christoph G. *How to use and assess qualitative research methods*. *Neurological Research and Practice*. 2020;2(1).
14. Braun V, Clarke V. Conceptual and design thinking for thematic analysis. *Qualitative psychology*. 2022;9(1):3.
15. Hosseini A, Jackson AC, Bahramnezhad F. Ethical Considerations in Interventional Studies: A Systematic Review Ethics and Interventional Study. *Acta Medica Iranica*. 2022:609-14.
16. Amin MEK, Nørgaard LS, Cavaco AM, Witry MJ, Hillman L, Cernasev A, et al. Establishing trustworthiness and authenticity in qualitative pharmacy research. *Research in social and administrative pharmacy*. 2020;16(10):1472-82.

17. Paramesha AE, Chacko LK. Predictors of adherence to antiretroviral therapy among PLHIV. *Indian Journal of Public Health*. 2019;63(4):367-76.
18. Drabble SJ, O’Cathain A, Arden MA, Hutchings M, Beever D, Wildman M. When is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments. *Qualitative health research*. 2019;29(14):2119-31.
19. Mate KK, Engler K, Lessard D, Lebouché B. Barriers to adherence to antiretroviral therapy: identifying priority areas for people with HIV and healthcare professionals. *International journal of STD & AIDS*. 2023;34(10):677-86
20. Areri HA, Marshall A, Harvey G. Interventions to improve self-management of adults living with HIV on antiretroviral therapy: a systematic review. *PloS one*. 2020;15(5):e0232709.
21. Glendinning E, Spiers J, Smith JA, Anderson J, Campbell LJ, Cooper V, et al. A qualitative study to identify perceptual barriers to antiretroviral therapy (ART) uptake and adherence in HIV positive people from UK black African and Caribbean communities. *AIDS and Behavior*. 2019;23:2514-21.
22. Saya U, Wagner Z, Mukasa B, Wabukala P, Lunkuse L, Linnemayr S. The role of material deprivations in determining ART adherence: Evidence from a conjoint analysis among HIV-positive adults in Uganda. *PLOS Global Public Health*. 2022;2(8):e0000374.
23. Lahai M, Theobald S, Wurie HR, Lakoh S, Erah PO, Samai M, et al. Factors influencing adherence to antiretroviral therapy from the experience of people living with HIV and their healthcare providers in Sierra Leone: a qualitative study. *BMC Health Services Research*. 2022;22(1):1327.

24. Tefera E, Mavhandu-Mudzusi AH. Experiences of antiretroviral therapy initiation among HIV-positive adults in Ethiopia: a descriptive phenomenological design. *HIV/AIDS-Research and Palliative Care*. 2022;243-54.
25. Opara HC, Iheanacho PN, Nebo B, Ingwu JA, Anetekhai CJ, Anarado AN. Factors affecting adherence to anti-retroviral therapy among women attending HIV clinic of a tertiary health institution in SouthEastern, Nigeria. *African Health Sciences*. 2022;22(1):456-64.
26. Addo MK, Aboagye RG, Tarkang EE. Factors influencing adherence to antiretroviral therapy among HIV/AIDS patients in the Ga West Municipality, Ghana. *IJID regions*. 2022;3:218-25.
27. Horne R, Chapman S, Glendinning E, Date HL, Guitart J, Cooper V. Mind matters: treatment concerns predict the emergence of antiretroviral therapy side effects in people with HIV. *AIDS and Behavior*. 2019;23:489-98.
28. Chijioke-Nwauche I, Akani Y. Influencing factors of adherence to antiretroviral drugs among people living with HIV in South-South Nigeria. *Saudi J Med Pharm Sci*. 2021;7(2):145-52.
29. Abdu M, Walelgn B. Determinant factors for adherence to antiretroviral therapy among adult HIV patients at Dessie Referral Hospital, South Wollo, Northeast Ethiopia: a case–control study. *AIDS Research and Therapy*. 2021;18:1-9.
30. Eze RA, Sulaiman N, Babadoko A, Eze R. Association Between Belief in Medicine and Adherence to Antiretroviral Therapy Among Human Immunodeficiency Virus Adults in Zaira, Kaduna State, Nigeria. *Cureus*. 2023;15(3).
31. Shrestha S, Chataut S, Kc B, Acharya K, Pradhan SK, Shrestha S. Knowledge, Attitude, Practice, and Adherence to Antiretroviral Therapy among People Living with HIV in Nepal. *AIDS research and treatment*. 2023;2023.

32. Castelan A, Nellen JF, van der Valk M, Nieuwkerk PT. Intentional-but not unintentional medication non-adherence was related with beliefs about medicines among a multi-ethnic sample of people with HIV. *AIDS and Behavior*. 2023;27(4):1045-54.
33. Dorcélus L, Bernard J, Georgery C, Vanessa C. Factors associated with antiretroviral therapy adherence among people living with HIV in Haiti: a cross-sectional study. *AIDS research and therapy*. 2021;18:1-9.
34. Metekiya WM, Wondafrash DZ, Tesfaw MT. Socio-Demographic and Clinical Correlates of Depressive Symptoms Prevalence and Severity Among People Living with Human Immunodeficiency Virus in Ethiopia: A Cross-Sectional Study. *The Open Public Health Journal*. 2020;13(1).
35. Fuge TG, Tsourtos G, Miller ER. Factors affecting optimal adherence to antiretroviral therapy and viral suppression amongst HIV-infected prisoners in South Ethiopia: a comparative cross-sectional study. *AIDS Research and Therapy*. 2022;19(1):5.
36. Getaye A, Cherie N, Bazie GW, Gebremeskel Aragie T. Proportion of depression and its associated factors among youth HIV/AIDS clients attending ART clinic in Dessie town government health facilities, Northeast Ethiopia. *Journal of Multidisciplinary Healthcare*. 2021:197-205.
37. Tegegne D, Mamo G, Negash B, Habte S, Gobena T, Letta S. Poor adherence to highly active antiretroviral therapy and associated factors among people living with HIV in Eastern Ethiopia. *SAGE Open Medicine*. 2022;10:20503121221104429.
38. Ahmed A, Dujaili JA, Jabeen M, Umair MM, Chuah L-H, Hashmi FK, et al. Barriers and enablers for adherence to antiretroviral therapy among people living with HIV/AIDS in the era of COVID-19: a qualitative study from Pakistan. *Frontiers in pharmacology*. 2022;12:807446.

39. Wanjala SW, Nyongesa MK, Mapenzi R, Luchters S, Abubakar A. A qualitative inquiry of experiences of HIV-related stigma and its effects among people living with HIV on treatment in rural Kilifi, Kenya. *Frontiers in Public Health*. 2023;11:1188446.
40. Beichler H, Kutalek R, Dorner TE. People Living with HIV and AIDS: Experiences towards Antiretroviral Therapy, Paradigm Changes, Coping, Stigma, and Discrimination—A Grounded Theory Study. *International Journal of Environmental Research and Public Health*. 2023;20(4):3000.
41. Becker N, Cordeiro LS, Poudel KC, Sibiya TE, Sayer AG, Sibeko LN. Individual, household, and community level barriers to ART adherence among women in rural Eswatini. *PloS one*. 2020;15(4):e0231952.
42. Johnson SR, Giordano TP, Markham C, Njue-Marendes S, Dang BN. Patients' experien
43. Chipps J, Dzansi G, Tornu E. Promoters and inhibitors of treatment adherence among HIV/AIDS patients receiving antiretroviral therapy in Ghana: Narratives from an underserved population. 2020.
44. Simelane PT, Simelane MS, Amoateng AY. Barriers and facilitators to adherence for antiretroviral therapy: the perspectives of patients from a wellness center in the Mpumalanga Province, South Africa. *African Health Sciences*. 2022;22(3):455-62.
45. Skovdal M, Maswera R, Kadzura N, Nyamukapa C, Rhead R, Wringe A, et al. Parental obligations, care and HIV treatment: How care for others motivates self-care in Zimbabwe. *Journal of Health Psychology*. 2020;25(13-14):2178-87.
46. Villiera JB, Katsabola H, Bvumbwe M, Mhango J, Khosa J, Silverstein A, et al. Factors associated with antiretroviral therapy adherence among adolescents living with HIV in the era of isoniazid preventive therapy as part of HIV care. *PLOS global public health*. 2022;2(6):e0000418.

47. Gebretsadik GG, Gebretnsae H, Ftwi M, Tesfahunegn A. Alarm Clock-Based reminder for improving low adherence on option B plus antiretroviral therapy among HIV positive pregnant and lactating mothers in Northern Ethiopia. *HIV/AIDS-Research and Palliative Care*. 2020;687-95.
48. Ndoro T, Ndlovu N, Nyasulu P. Factors associated with ART adherence among HIV-positive adherence club members in Ekurhuleni Metropolitan Municipality, South Africa: A cross-sectional study. *Plos one*. 2022;17(11):e0277039.
49. Saya U, MacCarthy S, Mukasa B, Wabukala P, Lunkuse L, Wagner Z, et al. “The one who doesn’t take ART medication has no wealth at all and no purpose on Earth”—a qualitative assessment of how HIV-positive adults in Uganda understand the health and wealth-related benefits of ART. *BMC Public Health*. 2022;22(1):1056.
50. Abdulai MA, Mevissen FE, Ruiter RA, Owusu-Agyei S, Asante KP, Bos AE. A qualitative analysis of factors influencing antiretroviral adherence among persons living with HIV in Ghana. *Journal of Community & Applied Social Psychology*. 2022;32(1):135-50.
51. Wahyuni S, Zulkifli A, Thamrin Y, Arsin AA. The effect of counseling on adherence arv therapy in HIV/AIDS patient in HA sulthan daeng radja bulukumba regency. *Enfermeria clinica*. 2020;30:362-6.